DelveInsight Evaluates a Robust Oligodendroglioma Pipeline as 10+ Influential Pharma Players to Set Foot in the Domain

DelveInsight's, "Oligodendroglioma Pipeline Insight, 2023," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in the Oligodendroglioma pipeline landscape. It covers the Oligodendroglioma pipeline drug profiles, including Oligodendroglioma clinical trials and nonclinical stage products. It also covers the Oligodendroglioma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

For Oligodendroglioma emerging drugs, the Oligodendroglioma pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The Oligodendroglioma pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.

In the Oligodendroglioma Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, Oligodendroglioma clinical trials studies, Oligodendroglioma NDA approvals (if any), and product development activities comprising the technology, Oligodendroglioma collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

Key takeaways from the Oligodendroglioma Pipeline Report

• Over 10+ Oligodendroglioma companies are evaluating 10+ Oligodendroglioma pipeline therapies in various stages of development, and their anticipated acceptance in the Oligodendroglioma market would significantly increase market revenue.

• The leading Oligodendroglioma Companies includes EpicentRx, Pfizer, Oblato, Istari Oncology, Bayer, Chimerix, Pfizer, Abbott, and others.

• Promising Oligodendroglioma Pipeline Therapies includes Palbociclib, RRx-001 dose escalation with TMZ + RT, Radiation, Etirinotecan Pegol, Toca 511, Toca FC, Temozolomide, Motexafin Gadolinium Injection, surgery, and others.

• The Oligodendroglioma companies and academics are working to assess challenges and seek opportunities that could influence R&D Oligodendroglioma. The Oligodendroglioma pipeline therapies under development are focused on novel approaches to treat/improve Oligodendroglioma.

Request a sample and discover the recent breakthroughs happening in the Oligodendroglioma Pipeline landscape, visit here @ Oligodendroglioma Pipeline Outlook Report- https://www.delveinsight.com/sample-request/oligodendroglioma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Oligodendroglioma Overview
Oligodendroglioma (OG) is a type of diffusely infiltrating glioma and constitutes approximately 5% of primary intracranial tumors. Oligodendroglial tumors can be divided into two groups based on the classification of the world health organization (WHO): grade II oligodendroglioma and grade III (anaplastic) oligodendroglioma. Most commonly occurring between 25 and 45 years of age, grade III oligodendrogliomas tend to present 10 years later than grade II tumors and can rarely develop in younger and older populations. Oligodendroglioma is genetically defined as a tumor confirmed to harbor either an IDH1 or IDH2 mutation along with co-deletion of chromosome arms 1p and 19q.

Latest Developmental Activities in the Oligodendroglioma Treatment Landscape

• In July 2021, Oblato announced that it received an agreement from the FDA for its plan to submit an intermediate size expanded access protocol for use of OKN-007 in patients with high-grade gliomas.

• In January 2021, Chimerix acquired Oncoceutics, a privately-held, clinical-stage biotechnology company developing imipridones, a novel class of compounds. Oncoceutics' lead product candidate, ONC201, in clinical testing to selectively induce cell death in multiple cancer types.

• In October 2018, Oblato acquired all rights from the Oklahoma Medical Research Foundation to OKN-007, an investigational drug for the treatment of glioblastoma, a deadly form of brain cancer.

• EpicentRx in collaboration with the Texas Children's Cancer Center in Houston, imitated the start of a Phase 1 study to examine the safety and benefit of its lead small molecule, RRx-001, plus irinotecan and temozolomide for pediatric patients with recurrent or progressive malignant solid and central nervous system tumors. The study, PIRATE (NCT04525014) was conceived and developed by doctors Holly Lindsay and Patricia Baxter at the Texas Children's Cancer Center and will enroll patients 1 to 21 years of age with recurrent or progressive malignant primary brain or spinal cord tumors and solid tumors, excluding lymphomas.

For further information, refer to the detailed Oligodendroglioma Unmet Needs, Oligodendroglioma Market Drivers, and Oligodendroglioma Market Barriers, click here for Oligodendroglioma Ongoing Clinical Trial Analysis @ https://www.delveinsight.com/sample-request/oligodendroglioma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Oligodendroglioma Emerging Drugs Profile

• ONC201: Chimerix

ONC201 is an orally administered small molecule dopamine receptor D2 (DRD2) antagonist and caseinolytic protease (ClpP) agonist in late-stage clinical development for recurrent gliomas that harbor the H3 K27M mutation. Recurrent glioma is a form of brain cancer with a particularly poor prognosis having a median overall survival of approximately eight months. Recurrent pediatric patients, with cancer that carries the H3 K27M mutation, have an even worse prognosis with median overall survival of approximately four months. Compelling responses at this stage of disease are rare and lack durability. Patients with this mutation are considered grade IV by the World Health Organization, regardless of underlying histology or age.

• RRx-001: EpicentRx

RRx-001 is a lead small molecule, immunotherapy targeting the CD47 - SIRPα axis and has been evaluated in multiple clinical studies. The genesis for the PIRATE trial was based on several preceding clinical trials which have established potential evidence that RRx-001 increases chemotherapy delivery and uptake in tumors. A Phase 1 clinical trial called G-FORCE (NCT02871843) and a Phase 1/2 clinical trial called BRAINSTORM (NCT02215512) demonstrated the safety of RRx-001 as well as potential evidence of clinical benefit in adult patients with glioblastoma or GBM and with brain metastases, respectively.

Oligodendroglioma Pipeline Therapeutics Assessment
There are approx. 10+ key companies which are developing the therapies Oligodendroglioma. The companies which have their Oligodendroglioma drug candidates in the most advanced stage, i.e. Phase II include, Pfizer.

Request a sample and discover the recent advances in Oligodendroglioma Ongoing Clinical Trial Analysis and Medications, click here for Oligodendroglioma Treatment Landscape @ https://www.delveinsight.com/sample-request/oligodendroglioma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Oligodendroglioma Pipeline Report

• Coverage- Global

• Oligodendroglioma Companies- EpicentRx, Pfizer, Oblato, Istari Oncology, Bayer, Chimerix, Pfizer, Abbott, and others.

• Oligodendroglioma Pipeline Therapies- Palbociclib, RRx-001 dose escalation with TMZ + RT, Radiation, Etirinotecan Pegol, Toca 511, Toca FC, Temozolomide, Motexafin Gadolinium Injection, surgery, and others.

• Oligodendroglioma Pipeline Segmentation: Product Type, Molecule Type, Mechanism of Action, Route of Administration

Dive deep into rich insights for drugs for Oligodendroglioma Market Drivers and Oligodendroglioma Market Barriers, click here for Oligodendroglioma Unmet Needs and Analyst Views @ https://www.delveinsight.com/sample-request/oligodendroglioma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Oligodendroglioma: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Oligodendroglioma- DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Product name: Company name
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. PD0332991: Pfizer
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. RRx-001: EpicentRx
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Oligodendroglioma Key Companies
21. Oligodendroglioma Key Products
22. Oligodendroglioma- Unmet Needs
23. Oligodendroglioma- Market Drivers and Barriers
24. Oligodendroglioma- Future Perspectives and Conclusion
25. Oligodendroglioma Analyst Views
26. Oligodendroglioma Key Companies
27. Appendix

Got Queries? Find out the related information on Oligodendroglioma Mergers and acquisitions, Oligodendroglioma Licensing Activities for Oligodendroglioma Emerging Drugs, and Recent Trends @ https://www.delveinsight.com/sample-request/oligodendroglioma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com

This release was published on openPR.